Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05260619 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma

Study acronym: PCNSL-LEM
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The study will include 28 patients with primary CNS DLBCL who are ineligible with autologous hematopoietic stem cell transplantation or whole brain radiation therapy as consolidation therapy. Induction treatment will include Rituximab and high dose methotrexate protocol (containing at least methotrexate and one more chemotherapy agent). Patients with MRI documented response CR or PR after induction chemotherapy will enter the study protocol of lenalidomide maintenance (at a dose of 15 mg per day, on days 1 to 21 of each 28-day cycle) for a maximum of 12 cycles, withdrew consent, the disease progressed, or unacceptable toxic effects occurred.
Trial Details
NCT Number NCT05260619
Lead Sponsor Seoul National University Bundang Hospital
Collaborators: Samyang BioPharm
Conditions
(from sponsor)		 Central Nervous System Lymphoma
Enrollment 28 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov